The following is an excerpt from the Plasma Protein Therapeutics Association. Read the full press release here.
The Board of Directors of the Plasma Protein Therapeutics Association announced Amy Efantis will be its next President and Chief Executive Officer effective Jan. 16, 2019.
Having served most recently as Vice President, Global Public Policy & Government Affairs at Biogen, Efantis joins the PPTA, the world’s leading trade association that represents more than 750 human plasma collection centers in North America and Europe as well as the manufacturers of life-saving plasma protein therapies.
Speaking on behalf of the PPTA’s Global Board of Directors, David Bell, Chairman of the PPTA’s Global Board of Directors and General Counsel and Chief Innovation Officer with Grifols SA, stated: “We are very pleased that Amy has agreed to take on the leadership for the PPTA at a time of unprecedented change in health care. Continued progress in the development of vital and life-saving treatments through the development of plasma protein therapies is critically dependent on the support needed from global stakeholders around the world. Amy has been selected by our Board as we all believe she has the leadership and vision to set the course for PPTA’s future.”
“I am thrilled and honored to be joining the PPTA and the vital efforts of the plasma industry,” said Efantis. She also observed that, “to represent companies whose mission is serving patients with rare diseases that can be treated through the development of plasma-derived products is a stewardship role that I embrace with humility and a deeply felt passion.”
Read the full press release in its entirety here.Â
